Study Evaluating IMA-026 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Registration Number
- NCT00517348
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Brief Summary
To assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IMA-026 administered subcutaneously (SC) or intravenously (IV) in healthy adults.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Pharmacokinetic (PK) analysis 6 months
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular targets or pathways does IMA-026 modulate in phase 1 trials of healthy subjects?
How does IMA-026's safety profile compare to other investigational agents in phase 1 healthy volunteer studies?
What biomarkers correlate with IMA-026's pharmacokinetics or pharmacodynamics in phase 1 trials?
What are the known adverse events of IMA-026 in phase 1 trials and their management strategies?
What other investigational drugs in the same class as IMA-026 are being developed by Pfizer or competitors?